Precision Biosciences Inc (DTIL) Stock Price, Quote & News

Company Profile

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with t...

Industry: Biotechnology

Sector: Healthcare

Phone: 919 314 5512

Fax: 480 393 5553

Website: precisionbiosciences.com

Address:

302 East Pettigrew St., Suite A-100, Durham, United States

Bob_Whitley Mar. 20 at 3:41 PM

$TGTX How is that $DTIL short doing these days? Looks like you got your face kicked in.

1 · Reply

steven1x Mar. 18 at 5:02 PM

$DTIL is this it? https://www.businesswire.com/news/home/20260318998536/en/iECURE-Selected-for-U.S.-FDA-Chemistry-Manufacturing-and-Controls-Development-and-Readiness-Pilot-Program-to-Support-Manufacturing-Readiness-of-ECUR-506-Ahead-of-Planned-BLA-Submission

2 · Reply

LoveRetailFroth Mar. 18 at 4:59 PM

$DTIL $70 🥪

0 · Reply

steven1x Mar. 18 at 4:56 PM

$DTIL why the lift?

0 · Reply

AlphaOfBiotech Mar. 18 at 4:12 PM

$DTIL $DTIL Go Go Go!!! Cheers 🥂 🥂🥂$FATE and $CRDF , which will be the next?

0 · Reply

Whiskeyunderthebed Mar. 18 at 3:56 PM

$TGTX I think the smarter play right now is $DTIL

2 · Reply

DARKP00L Mar. 18 at 12:08 PM

$DTIL 08:05 on Mar. 18 2026 iECURE's ECUR-506, And The Associated Nucleus Licensed From Precision BioSciences, Selected For FDA Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program #tradeideas

0 · Reply

Love_To_Learn Mar. 18 at 11:11 AM

$DTIL $AMTX $XFOR been raising u up and lately $LNZA

0 · Reply

Bio_Be_Dirty Mar. 17 at 11:22 PM

$DTIL what a month

0 · Reply

Love_To_Learn Mar. 17 at 5:37 PM

$DTIL $XFOR CONTINUED TO PUSH U 2 UP

0 · Reply

Precision BioSciences, Inc. (DTIL) Shareholder/Analyst Call Transcript

Mar 12, 2026, 7:00 AM EDT - 9 days ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update

Mar 11, 2026, 7:01 AM EDT - 10 days ago

Precision BioSciences Receives U.S. Patent Allowances Covering the PBGENE-HBV Program

Mar 10, 2026, 7:01 AM EDT - 11 days ago

Precision BioSciences Presents Preclinical PBGENE-DMD Data Highlighting Durable Dystrophin Expression and Functional Benefit at the Muscular Dystrophy Association Clinical & Scientific Conference 2026

Mar 9, 2026, 4:15 PM EDT - 12 days ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2025 Results on March 12, 2026

Mar 9, 2026, 7:01 AM EDT - 12 days ago

Precision BioSciences Receives FDA Fast Track Designation for PBGENE-DMD and Announces Duchenne Muscular Dystrophy Investor Event

Mar 2, 2026, 7:01 AM EST - 19 days ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

TGTX

Feb 18, 2026, 7:01 AM EST - 4 weeks ago

Precision BioSciences Announces Presentation at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Feb 11, 2026, 7:01 AM EST - 5 weeks ago

Precision BioSciences Receives U.S. FDA Clearance of Investigational New Drug Application for First-in-Class PBGENE-DMD for Treatment of Duchenne Muscular Dystrophy

Jan 12, 2026, 7:01 AM EST - 2 months ago

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy

Dec 29, 2025, 3:40 AM EST - 2 months ago

Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026

Dec 23, 2025, 7:00 AM EST - 3 months ago

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Dec 4, 2025, 6:38 AM EST - 3 months ago

Precision Biosciences: Still Swinging And Finally Drawing Blood

Nov 19, 2025, 7:01 AM EST - 4 months ago

Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025

Nov 11, 2025, 4:11 PM EST - 4 months ago

Precision BioSciences, Inc. (DTIL) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B Transcript

Nov 10, 2025, 6:12 PM EST - 4 months ago

Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants

Nov 10, 2025, 5:21 PM EST - 4 months ago

Precision BioSciences Presents Late-Breaking Phase 1 PBGENE-HBV Data at AASLD The Liver Meeting® Showing Safety, Tolerability and Cumulative, Dose-Dependent Antiviral Activity in First Three Cohorts

Nov 3, 2025, 7:01 AM EST - 4 months ago

Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 31, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 14, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting® 2025

Oct 9, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases

Oct 7, 2025, 7:01 AM EDT - 5 months ago

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial

Sep 30, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Announces Late-Breaking Poster Presentation at the 30th Annual International Congress of the World Muscle Society

Sep 16, 2025, 5:52 AM EDT - 6 months ago

Precision BioSciences, Inc. (DTIL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 12, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Presents Data from the Phase 1 ELIMINATE-B Trial of PBGENE-HBV at the 6th International Coalition to Eliminate HBV Cure Symposium

Sep 8, 2025, 7:01 AM EDT - 6 months ago

Precision BioSciences Announces U.S. Patent Covering PBGENE-HBV for Chronic Hepatitis B and Updates Program Status

Aug 7, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B

Aug 4, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025

Jul 23, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

Jul 16, 2025, 7:01 AM EDT - 8 months ago

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic

Jun 25, 2025, 7:01 AM EDT - 9 months ago

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy

May 15, 2025, 7:01 AM EDT - 11 months ago

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 4:30 PM EDT - 11 months ago

Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 8, 2025, 7:01 AM EDT - 11 months ago

Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025

May 7, 2025, 7:01 AM EDT - 11 months ago

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)

May 1, 2025, 7:01 AM EDT - 11 months ago

Precision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Apr 15, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B

Apr 1, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business Update

Mar 21, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025

Mar 20, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025

Mar 19, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 17, 2025, 7:01 AM EDT - 1 year ago

Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B

Mar 12, 2025, 8:00 AM EDT - 1 year ago

iECURE to Present Initial Data from Phase 1/2 OTC-HOPE Clinical Trial in Ornithine Transcarbamylase Deficiency at ACMG Annual Clinical Genetics Meeting

Feb 24, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 19, 2025, 2:27 PM EST - 1 year ago

Precision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment Candidate

Feb 19, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial

Jan 29, 2025, 7:01 AM EST - 1 year ago

Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs

Jan 10, 2025, 2:18 PM EST - 1 year ago

Precision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: Analyst

Bob_Whitley Mar. 20 at 3:41 PM

$TGTX How is that $DTIL short doing these days? Looks like you got your face kicked in.

1 · Reply

steven1x Mar. 18 at 5:02 PM

2 · Reply

LoveRetailFroth Mar. 18 at 4:59 PM

$DTIL $70 🥪

0 · Reply

steven1x Mar. 18 at 4:56 PM

$DTIL why the lift?

0 · Reply

AlphaOfBiotech Mar. 18 at 4:12 PM

$DTIL $DTIL Go Go Go!!! Cheers 🥂 🥂🥂$FATE and $CRDF , which will be the next?

0 · Reply

Whiskeyunderthebed Mar. 18 at 3:56 PM

$TGTX I think the smarter play right now is $DTIL

2 · Reply

DARKP00L Mar. 18 at 12:08 PM

0 · Reply

Love_To_Learn Mar. 18 at 11:11 AM

$DTIL $AMTX $XFOR been raising u up and lately $LNZA

0 · Reply

Bio_Be_Dirty Mar. 17 at 11:22 PM

$DTIL what a month

0 · Reply

Love_To_Learn Mar. 17 at 5:37 PM

$DTIL $XFOR CONTINUED TO PUSH U 2 UP

0 · Reply

Scrood_the_Pooch Mar. 17 at 5:24 PM

$DTIL Somebody wishing they were the "Patient_Investor" right about now.

1 · Reply

topstockalerts Mar. 17 at 5:16 PM

$DTIL When updates hit, this ticker can wake up fast. First wave of volume usually brings in short-term traders.

0 · Reply

Love_To_Learn Mar. 17 at 2:43 PM

$XFOR $DTIL !

0 · Reply

revuelto Mar. 16 at 11:23 PM

$DTIL a gift that keeps on giving ✌️

0 · Reply

Scrood_the_Pooch Mar. 16 at 9:00 PM

$DTIL Our resident clown-

0 · Reply

FoxyDreams Mar. 16 at 7:45 PM

/\ @SqueezeSharkie is playing on a completely different level, easily ahead of 90% of traders on this platform. If you’re not following him yet, you’re seriously missing out. Go hit that follow, it’s free and takes two seconds. 💎 $PURR $VANI $FWDI $DTIL >>><<< on watch

0 · Reply

FoxyDreams Mar. 16 at 7:35 PM

~@SqueezeSharkie is playing on a completely different level, easily ahead of 90% of traders on this platform. If you’re not following him yet, you’re seriously missing out. Go hit that follow, it’s free and takes two seconds.. $NBIS $DTIL $BOLT $COCH ^^ on watch

0 · Reply

topstockalerts Mar. 16 at 6:17 PM

$DTIL Traders often keep this on watchlists for headline driven reactions. If liquidity shows up after news, momentum can build fast.

0 · Reply

YoloAlfred Mar. 16 at 4:57 PM

$DTIL 😂🤣😅😂🤣$75 dollars a post just made $150 in 45 seconds

0 · Reply

YoloAlfred Mar. 16 at 4:55 PM

$DTIL 😎$75 dollars a post

0 · Reply

GuyFawkes_EOD Mar. 16 at 4:03 PM

$DTIL how much more does she have, got in at 4.87 🤔

0 · Reply

LoveRetailFroth Mar. 16 at 3:47 PM

$DTIL My Bio additions this yr $RCKT $RNAC $PALI $SMMT

0 · Reply

Market Cap	173.83M
Revenue (ttm)	34.26M
Net Income (ttm)	-45.72M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-133.45%
Debt to Equity Ratio	0.24

Volume	548,700
Avg Vol	269,324
Day's Range	N/A - N/A
Shares Out	24.73M
Stochastic %K	64%
Beta	1.28
Analysts	Strong Sell
Price Target	$32.00